FREQUENCY OF REBLEEDING IN THE FIRST 6 MONTHS AFTER BAND LIGATION IN DECOMPENSATED CHRONIC LIVER DISEASE PATIENTS
DOI:
https://doi.org/10.71000/27fh5w95Keywords:
decompensated chronic liver disease, endoscopic variceal ligation, , rebleeding, Child-Pugh classification, hypertension., diabetes mellitus , variceal haemorrhageAbstract
Background: Variceal bleeding is one of the most serious complications of decompensated chronic liver disease (DCLD) and is associated with high morbidity and mortality. Endoscopic variceal ligation (EVL) remains the preferred therapeutic option, yet early rebleeding continues to pose significant clinical challenges, particularly in patients with advanced hepatic dysfunction. Identifying predictive factors for recurrent haemorrhage is critical for risk stratification, tailoring surveillance strategies, and improving patient outcomes in high-burden, resource-limited settings.
Objective: To determine the clinical, demographic, and disease-related predictors associated with rebleeding within six months after EVL in patients with DCLD managed at Jinnah Postgraduate Medical Centre, Karachi.
Methods: This cross-sectional study was conducted between June 2023 and May 2024 and included 144 patients aged 40–70 years with a confirmed diagnosis of DCLD who underwent EVL. Patients with hepatocellular carcinoma, peptic ulcer disease, or significant systemic comorbidities were excluded. Demographic details, comorbid conditions such as diabetes mellitus, hypertension, and dyslipidemia, as well as liver disease severity using the Child–Pugh classification, were recorded. Patients were monitored through outpatient visits and telephone follow-ups for six months. Rebleeding was defined as clinically significant haemorrhage confirmed endoscopically between 24 hours and six months post-procedure. Data were analysed using SPSS version 20, with categorical variables assessed using chi-square tests and a significance level set at p ≤ 0.05.
Results: Rebleeding occurred in 28 out of 144 patients, yielding an incidence of 19.4%. Significant predictors of rebleeding included advanced liver disease (Child–Pugh Class C, p < 0.001), diabetes mellitus (18 out of 56 cases, p = 0.004), and hypertension (14 out of 48 cases, p = 0.028). Patients with Class C disease exhibited markedly higher recurrence, while smoking showed a non-significant association (p = 0.093).
Conclusion: Rebleeding following EVL remains a frequent complication in patients with advanced hepatic dysfunction and coexisting comorbidities. Early recognition of these high-risk groups is essential for optimizing management strategies and tailoring surveillance to reduce recurrence and improve clinical outcomes.
References
Association, A. D. (2022). Introduction: standards of medical care in diabetes—2022. Diabetes care, 45(Supplement_1), S1-S2.
Barbulescu, A., Ratiu, I., Sporea, I., Lungeanu, D., Lupusoru, R., Miutescu, B., Danila, M., Popescu, A., & Sirli, R. (2021). Extending and validating the Baveno VI criteria for the exclusion of high-risk varices. Medical Ultrasonography, 23(3), 265-270.
Cao, C., Jin, J., Cai, R., Chu, Y., Wu, K., Wang, Z., Xiao, T., Zhang, H., Huang, H., & Liu, H. (2024). Correlation between diameter of esophageal varices and early rebleeding following endoscopic variceal ligation: a multicenter retrospective study based on artificial intelligence-based endoscopic virtual rule. Frontiers in Medicine, 11, 1406108.
Chen, Y., Ming, W., Chen, J., Wang, X., & He, G. (2024). The impact of restrictive blood transfusion on the safety of patients with esophageal varices after endoscopic variceal ligation: A single-center retrospective study. Medicine, 103(33), e39407.
Hadaegh, F., Asgari, S., Moosaie, F., Orangi, M., Sarvghadi, F., Khalili, D., & Azizi, F. (2021). The risk and added values of the atherosclerotic cardiovascular risk enhancers on prediction of cardiovascular events: Tehran lipid and glucose study. Journal of Translational Medicine, 19(1), 25.
Jin, X., Wang, X., & Mao, P. (2022). Early Identification of High‐Risk Factors for Upper Gastrointestinal Bleeding. Evidence‐Based Complementary and Alternative Medicine, 2022(1), 5641394.
Lamarca, A., Barriuso, J., McNamara, M. G., & Valle, J. W. (2020). Molecular targeted therapies: ready for “prime time” in biliary tract cancer. Journal of hepatology, 73(1), 170-185.
Lin, C., & Huang, Y. (2025). Portal vein thrombosis and Esophageal-Gastric variceal bleeding in cirrhosis: shared risk factors and causal relationship. BMC gastroenterology, 25(1), 1-10.
Northup, P. G., Lisman, T., & Roberts, L. N. (2021). Treatment of bleeding in patients with liver disease. Journal of Thrombosis and Haemostasis, 19(7), 1644-1652.
Orpen-Palmer, J., & Stanley, A. J. (2022). Update on the management of upper gastrointestinal bleeding. BMJ medicine, 1(1), e000202.
Raţiu, I., Lupuşoru, R., Popescu, A., Sporea, I., Goldiş, A., Dănilă, M., Miuţescu, B., Moga, T., Barbulescu, A., & Şirli, R. (2022). Acute gastrointestinal bleeding: a comparison between variceal and nonvariceal gastrointestinal bleeding. Medicine, 101(45), e31543.
Ryu, H., Kim, T. U., Yoon, K. T., & Hong, Y. M. (2023). Predicting the risk of early bleeding following endoscopic variceal ligation in cirrhotic patients with computed tomography. BMC gastroenterology, 23(1), 410.
Tapper, E. B., Warner, M. A., Shah, R. P., Emamaullee, J., Dunbar, N. M., Sholzberg, M., Poston, J. N., Soto, R. J., Sarwar, A., & Pillai, A. (2024). Management of coagulopathy among patients with cirrhosis undergoing upper endoscopy and paracentesis: Persistent gaps and areas of consensus in a multispecialty Delphi. Hepatology, 80(2), 488-499.
Villa, E., Bianchini, M., Blasi, A., Denys, A., Giannini, E. G., de Gottardi, A., Lisman, T., de Raucourt, E., Ripoll, C., & Rautou, P.-E. (2022). EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis. Journal of hepatology, 76(5), 1151-1184.
Mertens A, Essing T, Kunstein A, Weigel C, Bode J, Roderburg C, et al. Acute Variceal Hemorrhage in Germany-A Nationwide Study of 65,357 Hospitalized Cases: Variceal Hemorrhage in Germany. Can J Gastroenterol Hepatol. 2024;2024:5453294.
Vashishtha C, Sarin SK. Bleeding Complications of Portal Hypertension. Clin Liver Dis. 2024;28(3):483-501.
Turco L, Reiberger T, Vitale G, La Mura V. Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension. Liver Int. 2023;43(6):1183-94.
Dunne PDJ, Young D, Chuah CS, Hayes PC, Tripathi D, Leithead J, et al. Carvedilol versus endoscopic band ligation for secondary prophylaxis of variceal bleeding-long-term follow-up of a randomised control trial. Aliment Pharmacol Ther. 2022;55(12):1581-7.
Singh S, Chandan S, Vinayek R, Aswath G, Facciorusso A, Maida M. Comprehensive approach to esophageal variceal bleeding: From prevention to treatment. World J Gastroenterol. 2024;30(43):4602-8.
Pfisterer N, Schwarz M, Jachs M, Putre F, Ritt L, Mandorfer M, et al. Endoscopic band ligation is safe despite low platelet count and high INR. Hepatol Int. 2023;17(5):1205-14.
Hayashi T, Watanabe T, Shibata M, Kumei S, Oe S, Miyagawa K, et al. Endoscopic injection sclerotherapy improves liver function compared with endoscopic variceal ligation. Sci Rep. 2021;11(1):20479.
Li Y, Du L, Zhang S, Liu C, Ma C, Liu X, et al. Endoscopic variceal ligation combined with carvedilol versus endoscopic variceal ligation combined with propranolol for the treatment of oesophageal variceal bleeding in cirrhosis: study protocol for a multicentre, randomised controlled trial. BMJ Open. 2025;15(4):e093866.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Avinash Kumar, Shabnam Naveed, Anjli, Shweta Kumari, Shewani Bai, Prem Chand (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
